{"id":74027,"date":"2013-03-07T00:04:11","date_gmt":"2013-03-07T05:04:11","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/bg-medicine-to-announce-fourth-quarter-and-year-end-2012-financial-results-and-host-conference-call-on-wednesday.php"},"modified":"2013-03-07T00:04:11","modified_gmt":"2013-03-07T05:04:11","slug":"bg-medicine-to-announce-fourth-quarter-and-year-end-2012-financial-results-and-host-conference-call-on-wednesday","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/bg-medicine-to-announce-fourth-quarter-and-year-end-2012-financial-results-and-host-conference-call-on-wednesday.php","title":{"rendered":"BG Medicine to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday &#8230;"},"content":{"rendered":"<p><p>      WALTHAM, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- BG      Medicine, Inc. (BGMD)      today announced that the company will host a conference call      and webcast on Wednesday, March 13 at 8:30 a.m. Eastern Time      to discuss its fourth quarter and year-end 2012 financial      results. The call and webcast will follow the release of the      fourth quarter financial results before the market opens.    <\/p>\n<p>      Conference Call Details    <\/p>\n<p>      To access the live conference call on March 13 at 8:30 a.m.      Eastern Time via phone, please dial (877) 845-1016 from the      U.S. and Canada, or (708) 290-1155 internationally. Please      dial in approximately ten minutes prior to the start of the      call.    <\/p>\n<p>      To access the live and subsequently archived webcast of the      conference call, go to the Investor Relations section of the      company's website       <a href=\"http:\/\/investor.bg-medicine.com\/events.cfm\" rel=\"nofollow\">http:\/\/investor.bg-medicine.com\/events.cfm<\/a>.      Please connect to the website at least 15 minutes prior to      the call to allow for any software download that may be      necessary.    <\/p>\n<p>      About BG Medicine    <\/p>\n<p>      BG Medicine, Inc. (BGMD)      is a diagnostics company focused on the development and      commercialization of novel cardiovascular tests to address      significant unmet medical needs, improve patient outcomes and      reduce healthcare costs. The Company has two products: the      BGM Galectin-3(R) test for use in patients with chronic heart      failure is available in the United States and Europe; and the      CardioSCORE(TM) test for the risk prediction of major      cardiovascular events will be launched in Europe in the first      half of 2013. For additional information about BG Medicine,      heart failure and galectin-3 testing, please visit <a href=\"http:\/\/www.bg-medicine.com\" rel=\"nofollow\">http:\/\/www.bg-medicine.com<\/a> and <a href=\"http:\/\/www.galectin-3.com\" rel=\"nofollow\">http:\/\/www.galectin-3.com<\/a>.    <\/p>\n<p>      The BG Medicine Inc. logo is available at       <a href=\"http:\/\/www.globenewswire.com\/newsroom\/prs\/?pkgid=10352\" rel=\"nofollow\">http:\/\/www.globenewswire.com\/newsroom\/prs\/?pkgid=10352<\/a>    <\/p>\n<\/p>\n<p><!-- Auto Generated --><\/p>\n<p>See the original post:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/bg-medicine-announce-fourth-quarter-133000549.html;_ylt=AwrjgkSrHzhRgHAAHAD_wgt.\" title=\"BG Medicine to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday ...\">BG Medicine to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> WALTHAM, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD) today announced that the company will host a conference call and webcast on Wednesday, March 13 at 8:30 a.m. Eastern Time to discuss its fourth quarter and year-end 2012 financial results.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/bg-medicine-to-announce-fourth-quarter-and-year-end-2012-financial-results-and-host-conference-call-on-wednesday.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-74027","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/74027"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=74027"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/74027\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=74027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=74027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=74027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}